That's easy. There are a ton of new drugs coming to market, esp. in the biotech arena, that will have to go through testing, which will mean lots of business for CVD. Any big outfit, eg. Abbott, in the pharmaceutical or any healthcare business, would be a possible suitor. I'm not saying its going to happen, but at these depressed prices it might make more sense for a potential client to buy them than to pay them to do their work.
Come on now. A pharma company would not buy a CRO. What would they do with all of the contracts that exist with their competitors? Confidentiality agreements would go out the window. The legal issues would be too expensive to sort out. Its not a viable option for a pharma company. Only a competitor or an other interested service industry company would bother.